Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              SHENZHEN SALUBRIS PHARMACEUTICALS CO.LTD.

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              CHINA China

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              ESMO 2020 Congress

              Participation Not Confirmed

              Update your events

              Carlyle to Acquire 5% Stake in Salubris, a Leading Biopharmaceutical Company in China

              Contact the Supplier

              Lead Product(s): JK07

              Therapeutic Area: Cardiology/Vascular Diseases Product Name: JK07

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: Carlyle

              Deal Size: $260.0 million Upfront Cash: Undisclosed

              Deal Type: Acquisition September 01, 2020

              Details:

              Salubris has developed a comprehensive innovative pipeline in the treatment of chronic diseases, including JK07, an innovative biologic drug treating heart failure which has filed for clinical trial approvals in both China and the United States.

              HUYA Bioscience International

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              CHINA China

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              ESMO 2020 Congress

              Participation Not Confirmed

              Update your events

              HUYA Bioscience International® Announces the Successful Completion of Phase 1 Trial of HBI-3000

              Contact the Supplier

              Lead Product(s): Sulcardine sulfate

              Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable February 28, 2020

              Details:

              Phase 2 trial will test the unique multi-channel ion blocker in acute atrial fibrillation.

              PharmaCompass__DigitalAd